Purpose of the new PQ financing strategy: • Maintain the overall objective of PQ to provide assured safe, efficacious and quality drugs, vaccines, diagnostics and devices while increasing supply and access; • Need for an innovative, practical and sustainable funding approach for the WHO PQ programme; • Reduce ...

Currently does not include estimates of number of people who may need PrEP (e.g. number of IDUs at high risk of HIV acquisition) or TasP • Borrows average usage forecast from currently available forecasts till 2018 • Borrows epidemiological estimates from available estimates till 2018 • Assumptions: – Linear ...

Background: Extent and timing of public health usage of ARVs, especially new drugs, was a key area for the MPP to understand when we commenced our licensing work with originator and generic companies • MPP started its forecasting exercise in 2011, including all ARVs but focusing on ...

WHO/UNAIDS Consultation with manufacturers. March 2015, Geneva, Switzerland Key Points • The IATT Optimal Formulary is designed to guide selection and procurement of paediatric ARV’s around a subset of optimal products • Consolidation of demand stabilizes supplies of paediatric ARVs • Success requires global consensus, cooperation with the manufacturers, ...

Forecasting demand for ARV's trends of pediatric formularions uptake from the GPRM Database

Objectives: Promote access to life saving medicines and informed the WHO guideline Process; Work with all concerned parties to remove or minimize obstacles for medicines entering the market and facilitate their uptake; Provide partners and players in the field of SCM with reliable data to ...

Forecast numbers of patients on ARVs and demand for individual ARVs in low and middle-income countries for 2014 to 2018 using best available evidence. Data sources include: • WHO ARV Survey • GPRM procurements • CHAI forecasts • UNAIDS estimates of need for ART • Global Fund quantification of ARV ...

Forecasting demand for ARV's is the current API production capacity sufficient to meet the growing ARV demand for a smooth procurement?

The global effort to scale-up HIV treatment in low- and middle-income countries continues to move closer towards achieving the goal of 15 million people receiving treatment by 2015. By the end of 2012, 9.7 million people in low- and middle-income countries were receiving antiretroviral therapy ...

Strategic information collected on these indicators will show progress towards the 90-90-90 targets by UNAIDS: By 2020, 90% of all people living with HIV will have been diagnosed. By 2020, 90% of all people with diagnosed HIV infection will receive antiretroviral therapy. By 2020, 90% ...

Updates on hepatitis B and C treatment guidelines and overview of hepatitis treatment landscape.

The paper provides information on the prices paid by 20 middle-income countries for adult and paediatric formulations of antiretroviral (ARV) drugs recommended by the World Health Organization (WHO). It links this information with an analysis of the intellectual property situation of the selected ARV medicines ...

This paper forms part of Phase 2 of a project undertaken by the World Health Organization and supported by the European Commission on improving access to medical products in developing countries through building capacity for local production and related technology transfer. Phase 1 of the project ...

HIV testing in presumptive & diagnosed TB cases is effective at identifying PLHIV & saving lives in all settings Reaching the first 90%, will help to diagnose 90% of HIV-related TB. Co-location and integration facilitates scale-up and increases access in both generalized and concentrated ...